People: Ablynx NV (ABLX.BR)
Dr. Russell G. Greig, Ph.D., serves as Independent Member of the Board of Directors of Ablynx NV. He has more than 30 years of experience in the pharmaceutical industry, with knowledge in research and development, business development and commercial operations. He spent the majority of his career at GlaxoSmithKline, where he held a number of positions including GSK’s President of Pharmaceuticals International from 2003 to 2008 and Senior Vice President Worldwide Business Development. From 2008 to 2010, he was also President of SR One, GSK’s Corporate Venture Group. He is currently Chairman of Syntaxin (the United Kingdom), AM Pharma (The Netherlands) and Isconova (Sweden) as well as Director of Tigenix (Belgium). He also acts as a Consultant to Genocea (the United States), BigDNA (Scotland), Edinburgh BioQuarter (Scotland), and Kurma Life Sciences (France). He served as acting Chief Executive Officer at Genocea and Isconova for an interim period. He is also Member of the Scottish Scientific Advisory Committee. He holds a Bachelor of Science degree from the University of Manchester and a Doctorate in Philosophy degree in Biochemistry from the University of Manchester.
|Total Annual Compensation,||Long-Term Incentive Plans,||All Other,||Fiscal Year Total,|